# Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

> **NCT02196701** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 46 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02196701
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-05
- **Primary completion:** 2017-03-17
- **Final completion:** 2017-03-17
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196701, "Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02196701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*